Post-transition: Pharmacovigilance requirements for UK authorised products webinar recording, which took place on 22 October 2020. This webinar was part of a series of EU Exit and post-transition guidance webinars.
Kiernan is a Senior Pharmacovigilance Inspector and she joined the MHRA GPvP Inspectorate in April 2012. Her background is in Quality Assurance auditing for a central laboratory providing services for Phase I-III pharmaceutical clinical trials. Kiernan has a Master’s degree in Biomedical Sciences from the University of Southampton.
Many marketing authorisation holders (MAHs) sponsor and run a wide variety of programmes that are often internally termed a ‘patient support programme’ (PSP) and we are often asked by industry about the expectations for the collection of safety data from these programmes.
The MHRA GPvP inspectorate recently published their latest inspection metrics for the period of April 2016 to March 2017.
Risk minimisation measures aim to optimise the safe and effective use of a medicinal product throughout its life cycle.
In July 2003 the Medicines and Healthcare products Regulatory Agency (MHRA) introduced a statutory pharmacovigilance inspection programme of marketing authorisation holders (MAHs) in the United Kingdom. The revisions to the pharmacovigilance legislation implemented in 2012 are supportive of the inspection of …
The MHRA GPvP inspectorate recently published their latest inspection metrics for the period of April 2014 to March 2015. The full metrics report is available on GOV.UK. The report concludes that in the period April 2014 to March 2015, MHRA conducted a …
The Medicines and Healthcare products Regulatory Agency (MHRA) has embarked on a recent initiative to evaluate the feasibility of conducting stand-alone inspections of pharmacovigilance contract service providers. In July 2003 MHRA introduced a statutory pharmacovigilance inspection programme of marketing authorisation …
Related content and links
About the MHRA Inspectorate Blog
This blog shares the work of the Medicines and Healthcare products Regulatory Agency (MHRA) Inspectorate, by inspectors and those the Inspectorate works with.
MHRA Inspectorate & Process Licensing Organogram
Other MHRA Blogs
Comments and moderation
- Post-transition: Pharmacovigilance requirements for UK authorised products - Thursday 22 October 2020
- Qualifications of suppliers and customers online: reliable or fake news?
- Professor Taylor on being the Chair of The British Pharmacopoeia Commission
- Building resilience into clinical trial design and conduct during the pandemic
- A fresh look at an old topic: Investigations in the GMDP environment